


Add-On Treatment with Pipamperon 8-12 (mean 9) mg (bid) after Treatment with Citalopram 10-20 (mean 30) mg (bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17 Totalscore = 29 at Baseline in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57 / APR 2000

Figure 1

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (duloxetine) in MAJOR DEPRESSION




Figure 2

REMISSION RATES (HDRS-17 ≤ 7): COMBO PIPAMPERON AS ADD- ON - CITALOPRAM vs SNRI (venlafaxine) vs SSRI's vs PLACEBO in MAJOR DEPRESSION





Figure 3

Foregoing Treatment During 1-5 (mean 4) days with Pipamperon 8-12 (mean 10) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-50 (mean 26) mg/day (bid) (PICIT FG 1-5) in MDD (HDRS-17 at BL = 23) in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



* A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY/VOL 57/APR 2000

Figure 4

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION




Figure 5

REMISSION RATES (HDRS-17 ≤ 7): COMBO PIPAMPERON-CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (venlafaxine) in MAJOR DEPRESSION





Figure 6

Foregoing Treatment During 6-8 (mean 7) days with Pipamperon 8-12 (mean 11) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-40 (mean 30) mg/day (bid) (PICIT FG 6-8) in MDD (HDRS-17 at BL = 28 in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY/VOL 57/APR 2000)

Figure 7

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 7 DAYS WITH PIPAMPERON 11mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION





Figure 8

Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



* A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57, APR 2000)

Figure 9

HDRS-17 CHANGE FROM BASELINE: Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI duloxetine in MAJOR DEPRESSION




Figure 10

REMISSION RATES (HDRS-17 ≤ 7): Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI venlafaxine in MAJOR DEPRESSION





Figure 11

**Y-BOCS TOTALSCORE: Foregoing & Add-On Treatment with
Pipamperon 8-16 mg/day (bid) and Citalopram 30-80 mg/day (bid)
in comparison with the SSRI fluvoxamine in OCD**



COMBO PIPAMPERON-CITALOPRAM (n=7)

FLUVOXAMINE Controlled Release mean
271 mg/day (n=253) (Hollander E, Journal of
Clinical Psychiatry 64: 640-647, Jun 2003)

Figure 12

**Y-BOCS OBSESSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**




Figure 13

**Y-BOCS COMPULSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**




Figure 19

CGI-SEVERITY SCORE: Foregoing & Add-On Treatment with Pipamperon 8 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the

SSRI in Panic Disorder




Figure 15